J&J Innovative Medicine’s continuous R&D investments, totaling over $90 billion since 2016, are helping save lives today and bringing hope to patients tomorrow.  Yet, patients’ affordable access to lifesaving medicines is becoming harder each year because of increasing out-of-pocket costs, inadequate insurance benefit design and regulatory hurdles.

The 340B Drug Pricing Program was designed to help eligible safety-net healthcare providers provide access to more affordable medicines for low-income and vulnerable patients. Unfortunately, patients today are not directly benefiting from the program amidst widespread abuse and misuse.